These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35296005)

  • 21. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
    Bowman CJ; Zhang R; Balitzer D; Wang D; Rabinovitch PS; Kővári BP; Mattis AN; Kakar S; Lauwers GY; Choi WT
    Mod Pathol; 2021 Oct; 34(10):1889-1900. PubMed ID: 34108638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Cryotherapy as a Primary Endoscopic Ablation Modality for Dysplastic Barrett's Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-Analysis.
    Tariq R; Enslin S; Hayat M; Kaul V
    Cancer Control; 2020; 27(1):1073274820976668. PubMed ID: 33297725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of recurrence of dysplasia or cancer in patients with dysplastic Barrett's esophagus following complete eradication of dysplasia: a single-center retrospective cohort study.
    Kobayashi R; Calo NC; Marcon N; Iwaya Y; Shimamura Y; Honda H; Streutker C; Mosko J; May G; Teshima C
    Surg Endosc; 2022 Jul; 36(7):5041-5048. PubMed ID: 34750708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic therapy of esophageal premalignancy and early malignancy.
    Nealis TB; Washington K; Keswani RN
    J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial.
    Cotton CC; Wolf WA; Overholt BF; Li N; Lightdale CJ; Wolfsen HC; Pasricha S; Wang KK; Shaheen NJ;
    Gastroenterology; 2017 Sep; 153(3):681-688.e2. PubMed ID: 28579538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.
    Orman ES; Kim HP; Bulsiewicz WJ; Cotton CC; Dellon ES; Spacek MB; Chen X; Madanick RD; Pasricha S; Shaheen NJ
    Am J Gastroenterol; 2013 Feb; 108(2):187-95; quiz 196. PubMed ID: 23247578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of endoscopic submucosal dissection (ESD) plus radiofrequency ablation (RFA) for nodular Barrett's esophagus.
    Bahdi F; Katti CC; Mansour N; Gagneja H; Anandasabapathy S; Othman MO
    Scand J Gastroenterol; 2023 Feb; 58(2):123-132. PubMed ID: 35968576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
    O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
    Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: results of the National Cryospray Registry.
    Ghorbani S; Tsai FC; Greenwald BD; Jang S; Dumot JA; McKinley MJ; Shaheen NJ; Habr F; Coyle WJ
    Dis Esophagus; 2016 Apr; 29(3):241-7. PubMed ID: 25708903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Controversies in Radiofrequency Ablation Therapy for Barrett's Esophagus.
    Belghazi K; Cipollone I; Bergman JJ; Pouw RE
    Curr Treat Options Gastroenterol; 2016 Mar; 14(1):1-18. PubMed ID: 26891725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
    Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
    Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of low-grade dysplasia in Barrett's esophagus.
    Wani S
    Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A narrative review of Barrett's esophagus in 2020, molecular and clinical update.
    Dam AN; Klapman J
    Ann Transl Med; 2020 Sep; 8(17):1107. PubMed ID: 33145326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.
    Shimamura Y; Iwaya Y; Kobayashi R; Rodriguez de Santiago E; Muwanwella N; Raftopoulos S; Mosko JD; May GR; Kandel G; Kortan P; Marcon N; Teshima CW
    Surg Endosc; 2021 Oct; 35(10):5468-5479. PubMed ID: 32989547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett's esophagus may not be benign.
    Cameron GR; Desmond PV; Jayasekera CS; Amico F; Williams R; Macrae FA; Taylor AC
    Endosc Int Open; 2016 Aug; 4(8):E849-58. PubMed ID: 27540572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.